Stock Events

Stock Events

Hepion Pharmaceuticals 

$0.001300
27
+$0.00+0% Friday 20:00

Statistics

Day High
0.0013
Day Low
0.0013
52W High
0.0013
52W Low
0.0013
Volume
10
Avg. Volume
0
Mkt Cap
37,856
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

14OctExpected
Q3 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Next
-98.5
-65.69
-32.88
-0.07
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-8.28MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CTRVP. It's not an investment recommendation.
Apple
6
AAPL
Microsoft
5
MSFT
Tesla
5
TSLA
AT&T
5
T

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap187.23B
Gilead Sciences is a leading biopharmaceutical company that develops and markets drugs for life-threatening illnesses including liver disease, a key area of focus for Hepion Pharmaceuticals.
Vertex Pharmaceuticals
VRTX
Mkt Cap138.42B
Vertex Pharmaceuticals is involved in creating treatments for serious diseases, including liver diseases, which puts it in direct competition with Hepion Pharmaceuticals' efforts in NASH and liver-related treatments.
Madrigal Pharmaceuticals
MDGL
Mkt Cap12.5B
Madrigal Pharmaceuticals focuses on the development of novel therapies for cardiovascular, metabolic, and liver diseases, including NASH, making it a competitor in Hepion's market space.
Viking Therapeutics
VKTX
Mkt Cap4.07B
Viking Therapeutics is working on treatments for metabolic and endocrine disorders, including NASH, positioning it as a competitor to Hepion Pharmaceuticals in the NASH treatment market.
Galmed Pharmaceuticals
GLMD
Mkt Cap4.14M
Galmed Pharmaceuticals is engaged in the development of oral therapies for the treatment of liver diseases, including NASH, competing with Hepion Pharmaceuticals in the liver disease therapeutic area.
Agios Pharmaceuticals
AGIO
Mkt Cap1.98B
Agios Pharmaceuticals focuses on cellular metabolism and rare genetic diseases, including metabolic and liver-related diseases, making it a competitor in the broader market for liver disease treatments.
Enanta Pharmaceuticals
ENTA
Mkt Cap410.09M
Enanta Pharmaceuticals is focused on creating treatments for liver diseases and respiratory infections, with a significant focus on liver diseases, making it a competitor to Hepion.

About

HEPION PHARM INC PFD
Show more...
CEO
Gary S. Stetz
Country
United States
ISIN
US4268972035

Listings

STU
DE
3360.STU
STU
DE
336N.STU
MU
DE
3360.MU
OTC Link
US
HEPA

0 Comments

Share your thoughts

FAQ

What is Hepion Pharmaceuticals stock price today?▼
The current price of CTRVP is $0.00 USD — it has increased by +0% in the past 24 hours. Watch Hepion Pharmaceuticals stock price performance more closely on the chart.
What is Hepion Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Hepion Pharmaceuticals stocks are traded under the ticker CTRVP.
What is Hepion Pharmaceuticals market cap?▼
Today Hepion Pharmaceuticals has the market capitalization of 37,856
When is the next Hepion Pharmaceuticals earnings date?▼
Hepion Pharmaceuticals is going to release the next earnings report on October 14, 2026.
What is Hepion Pharmaceuticals revenue for the last year?▼
Hepion Pharmaceuticals revenue for the last year amounts to 0 USD.
What is Hepion Pharmaceuticals net income for the last year?▼
CTRVP net income for the last year is -8.28M USD.
In which sector is Hepion Pharmaceuticals located?▼
Hepion Pharmaceuticals operates in the Health & Wellness sector.
When did Hepion Pharmaceuticals complete a stock split?▼
The last stock split for Hepion Pharmaceuticals was on March 18, 2025 with a ratio of 1:50.
Where is Hepion Pharmaceuticals headquartered?▼
Hepion Pharmaceuticals is headquartered in Morristown, United States.